8-K filing — CRESCENT BIOPHARMA, INC. (CBIO)
Filed: 2026-10-15 AccNo: 0001628280-26-066006 Size: 157 KB Item 8.01: Other Events
Stocks · News reference
Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crescent Biopharma Says Initial Data From Phase 1/2 CR-001 Trial On Track For Q1 2027; Sees Potential Phase 3 Start In Early 2028
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.